

In the Claims:

1. (Currently amended) An in vitro method for disrupting the binding of p53 and p53-binding protein mdm2 in a population of cancer cells in which said p53-binding protein mdm2 is not overexpressed, comprising administering to the cells a peptide, less than 25 amino acids in length, and comprising SEQ ID NO: 3.

2. (Previously presented) The method of claim 1 wherein the p53 is activated for DNA specific binding and transcription.

3-7. (Canceled)

8. (Currently amended) The method of claim 1 wherein the peptide has the property of competing with said p53-binding protein mdm2 for binding p53, but does not inhibit DNA specific binding property of p53.

9-27. (Canceled)